Neoadjuvant B-RAF and MEK Inhibitor Targeted Therapy for Adult Papillary Craniopharyngiomas: A New Treatment Paradigm

Overview of attention for article published in Frontiers in endocrinology, June 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (69th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

So far, Altmetric has seen 9 X posts from 7 X users, with an upper bound of 11,805 followers.

RT @GeraldRaverot: Our new publication @HCL_research on Neoadjuvant B-RAF and MEK Inhibitor Targeted Therapy for Adult Papillary #Cranioph…

RT @GeraldRaverot: Our new publication @HCL_research on Neoadjuvant B-RAF and MEK Inhibitor Targeted Therapy for Adult Papillary #Cranioph…

Our new publication @HCL_research on Neoadjuvant B-RAF and MEK Inhibitor Targeted Therapy for Adult Papillary #Craniopharyngiomas: A New Treatment Paradigm https://t.co/8JTDgGTj1v more to come @ENEAssoc @ENEA_Young #ENEA2022 meeting in Lyon

Neoadjuvant B-RAF and MEK Inhibitor Targeted Therapy for Adult Papillary Craniopharyngiomas: ... https://t.co/EgjPHO9Fko

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 5 additional X posts.